Literature DB >> 7840568

Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.

D Jabès1, C Della Bruna, R Rossi, P Olliaro.   

Abstract

The ever-increasing incidence of tuberculosis calls for the implementation of control measures, including new efficient, short-term preventive therapies to replace 6 to 12 months of isoniazid therapy. The efficacies of 12-week regimens of rifabutin or isoniazid given daily and the combination of the two drugs administered intermittently were evaluated in mice infected with Mycobacterium tuberculosis after vaccination with the bacillus Calmette-Guérin (BCG) to imitate some features of the natural infection in humans with a low number of persisting bacteria. Rifabutin at 10 mg/kg of body weight per day was highly effective as early as the eighth week of treatment: all spleens were sterilized and the number of bacteria was drastically reduced in the lungs (mean +/- standard deviation log CFU, 0.2 +/- 0.3, compared with 5.9 +/- 0.6 for untreated controls). No bacilli were found in the spleens or lungs of any of the animals treated for 12 weeks. The combination of rifabutin at 10 mg/kg plus isoniazid at 25 mg/kg twice weekly was almost as effective as rifabutin daily: after 8 weeks of treatment only two of six mice harbored a small number of mycobacteria in their spleens and lungs; at week 12, all spleens were sterilized and a total of eight colonies were isolated from the lungs of two of six mice. Daily isoniazid and once-weekly rifabutin plus isoniazid therapies were less effective. Colonies randomly isolated from the spleens and lungs of mice from different experimental groups were also tested for their susceptibilities to the two drugs. The three surviving colonies from rifabutin-treated mice and all colonies from those administered rifabutin plus isoniazid remained fully susceptible to either drug. In contrast, 2 (18%) of the 11 colonies randomly selected from isoniazid-treated mice became resistant to isoniazid (MIC, > 2 micrograms/ml), although they were still susceptible to rifabutin. Three months of treatment with rifabutin, either daily alone or twice a week combined with isoniazid, proved to be a valid candidate for tuberculosis preventive therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840568      PMCID: PMC284742          DOI: 10.1128/AAC.38.10.2346

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.

Authors:  H F Lecoeur; C Truffot-Pernot; J H Grosset
Journal:  Am Rev Respir Dis       Date:  1989-11

Review 2.  Isoniazid-associated hepatitis deaths: a review of available information.

Authors:  D E Snider; G J Caras
Journal:  Am Rev Respir Dis       Date:  1992-02

3.  Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy.

Authors:  D E Snider; G J Caras; J P Koplan
Journal:  JAMA       Date:  1986-03-28       Impact factor: 56.272

4.  Intraphagocytic penetration of antibiotics.

Authors:  P Van der Auwera; T Matsumoto; M Husson
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

5.  Less is more: short-course preventive therapy of tuberculosis.

Authors:  M D Iseman
Journal:  Am Rev Respir Dis       Date:  1989-11

6.  In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1987-09

7.  Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy; M D Iseman
Journal:  Am Rev Respir Dis       Date:  1988-03
  7 in total
  5 in total

1.  Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis.

Authors:  B P Kelly; S K Furney; M T Jessen; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

2.  Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.

Authors:  J V Brooks; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

3.  Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics.

Authors:  Muhammad Miftahussurur; Hafeza Aftab; Pradeep Krishna Shrestha; Rabi Prakash Sharma; Phawinee Subsomwong; Langgeng Agung Waskito; Dalla Doohan; Kartika Afrida Fauzia; Yoshio Yamaoka
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-15       Impact factor: 4.887

4.  Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic.

Authors:  Muhammad Miftahussurur; Modesto Cruz; Dalla Doohan; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Langgeng Agung Waskito; Yoshio Yamaoka
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

5.  A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis.

Authors:  Manse Kim; Claire E Johnson; Alan A Schmalstig; Ayano Annis; Sarah E Wessel; Brian Van Horn; Amanda Schauer; Agata A Exner; Jason E Stout; Angela Wahl; Miriam Braunstein; J Victor Garcia; Martina Kovarova
Journal:  Nat Commun       Date:  2022-08-08       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.